ArticleCancer medicine2023
Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.Cancer chemotherapy and pharmacology · 2026Pooled it
- Factors influencing pharmacokinetics of 5-fluorouracil in cancer patients: a systematic review of population pharmacokinetic models.European journal of clinical pharmacology · 2026Pooled it
- Integrating CT-Derived Body Composition and Real-Time Injection Pressure Monitoring for Predicting Contrast Media Extravasation: A Retrospective Cohort Study with Implications for Nurse-Led Risk Stratification.Healthcare (Basel, Switzerland) · 2026Article
- Technical performance of L3 skeletal muscle area (SMA) measurement on CT for L3 skeletal muscle index (L3SMI) assessment.Scientific reports · 2026Article
- Postoperative malnutrition predicts severe chemotherapy toxicity after gastrectomy: evaluation of an inflammation-anemia phenotype.Open medicine (Warsaw, Poland) · 2026Article
- Cisplatin-Induced Skeletal Muscle Atrophy: Biomolecular Mechanisms and the Protective Role of Exercise-Induced Myokines.Biomolecules · 2025Review
- Comparing Scientific Machine Learning With Population Pharmacokinetic and Classical Machine Learning Approaches for Prediction of Drug Concentrations.CPT: pharmacometrics & systems pharmacology · 2025Article
- Pharmacokinetics of cancer therapeutics and energy balance: the role of diet intake, energy expenditure, and body composition.Journal of the National Cancer Institute. Monographs · 2023Review
- Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil.Cancer medicine · 2023Article
- The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.PloS one · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe body composition of patients has been associated with tolerability and effectiveness of anticancer therapy. This study aimed to assess the influence of the skeletal muscle index (SMI) on the pharmacokinetics and toxicity of fluorouracil.
methodsPatients treated in an oncological practice with fluorouracil-based chemotherapy and undergoing therapeutic drug monitoring were retrospectively investigated. Computed tomography images were analyzed to measure abdominal skeletal muscle areas in Hounsfield units for the psoas major muscle, back and total skeletal muscle to determine the SMI. For the latter, an automated segmentation method was used additionally. SMI measures were tested as covariates on fluorouracil clearance in a population pharmacokinetic model. Furthermore, regression analyses were performed to analyze the influence of SMI measures on the probability of clinically relevant adverse events (CTCAE grades ≥ 2).
resultsFluorouracil plasma concentrations of 111 patients were available. Covariate analyses showed significant improvements of the model fit by all SMI measures. However, interindividual variability of fluorouracil clearance was only slightly reduced, whereas the SMI of the back muscle showed the largest reduction (-1.1 percentage points). Lower SMI values of the back muscle increased the probability for polyneuropathy and lower SMI of the psoas increased the probability for fatigue.
conclusionsOur results suggest that pharmacokinetics and toxicity of fluorouracil may be associated with specific SMI measures which deserve further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.